A detailed history of Ensign Peak Advisors, Inc transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 611,814 shares of IDYA stock, worth $16.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
611,814
Previous 483,714 26.48%
Holding current value
$16.4 Million
Previous $17 Million 14.13%
% of portfolio
0.03%
Previous 0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.37 - $43.05 $3.89 Million - $5.51 Million
128,100 Added 26.48%
611,814 $19.4 Million
Q2 2024

Aug 13, 2024

SELL
$34.37 - $43.46 $160,026 - $202,349
-4,656 Reduced 0.95%
483,714 $17 Million
Q1 2024

May 14, 2024

SELL
$34.2 - $47.13 $57,079 - $78,659
-1,669 Reduced 0.34%
488,370 $21.4 Million
Q4 2023

Feb 14, 2024

BUY
$24.59 - $35.83 $3.1 Million - $4.52 Million
126,255 Added 34.71%
490,039 $17.4 Million
Q3 2023

Nov 13, 2023

BUY
$21.07 - $29.77 $2.75 Million - $3.88 Million
130,350 Added 55.84%
363,784 $9.81 Million
Q2 2023

Aug 14, 2023

BUY
$13.33 - $25.53 $1.88 Million - $3.6 Million
141,023 Added 152.6%
233,434 $5.49 Million
Q4 2022

Feb 13, 2023

SELL
$14.47 - $18.17 $112,287 - $140,999
-7,760 Reduced 7.75%
92,411 $1.68 Million
Q3 2022

Nov 14, 2022

BUY
$9.24 - $15.79 $49,803 - $85,108
5,390 Added 5.69%
100,171 $1.5 Million
Q1 2022

May 16, 2022

BUY
$11.18 - $24.02 $26,496 - $56,927
2,370 Added 2.56%
94,781 $1.06 Million
Q4 2021

Feb 11, 2022

BUY
$20.95 - $26.88 $1.16 Million - $1.49 Million
55,496 Added 150.33%
92,411 $2.19 Million
Q3 2020

Nov 12, 2020

BUY
$11.22 - $14.46 $414,186 - $533,790
36,915 New
36,915 $464,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.29B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.